Seagen, Genmab See Broad Cervical Cancer Opportunity For Tisotumab Vedotin
US FDA Clears Monotherapy Use
Executive Summary
At ESMO, data showed objective response benefit in combination with carboplatin in first-line therapy, and with Keytruda in second- or third-line treatment. The antibody-drug conjugate obtained US approval on 20 September as monotherapy.
You may also be interested in...
Asia Deal Watch: Astellas Seeks Pantherna’s Assistance On mRNA-Based Regenerative Medicine
Plus deals involving OliPass/Vanda, Simcere/Almirall, Sinopharm/Merck & Co., Jiuzhou/Sandoz, Zai Lab/Seagen, Sciwind/SynderK, Hansoh/KiOmed.
Keytruda Expands Cervical Cancer Position With ESMO Data
In addition to securing a key position in first-line disease, Keytruda has potential to expand its presence in later lines with combination data from Seagen/Genmab’s Tivdak.
GSK’s Blenrep Wins BCMA Race, Carries Ocular Toxicity Warning
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.